Third Harmonic Bio Inc.

NASDAQ THRD

Download Data

Third Harmonic Bio Inc. Non-current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -27.00%

Third Harmonic Bio Inc. Non-current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is -27.00% for the Trailing 12 Months (TTM) ending March 31, 2024, a 31.57% change year over year. The total non-current liabilities to total liabilities ratio measures the proportion of a company's non-current liabilities to its total liabilities. It is calculated by dividing the total non-current liabilities by the total liabilities. This ratio provides insights into the composition of a company's liabilities and the extent to which it relies on long-term debt and obligations. A higher ratio indicates a greater reliance on non-current liabilities, suggesting potential long-term financial commitments and increased financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Third Harmonic Bio Inc. Non-current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.59, a -39.46% change year over year.
  • Third Harmonic Bio Inc. Non-current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.97.
NASDAQ: THRD

Third Harmonic Bio Inc.

CEO Ms. Natalie C. Holles
IPO Date Sept. 14, 2022
Location United States
Headquarters 300 Technology Square, Cambridge, MA, United States, 02139
Employees 31
Sector Healthcare
Industry Biotechnology
Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Similar companies

NXTC

NextCure  Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

RLYB

Rallybio Corp

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email